Leverkusen, January 16, 2020 – Bayer and WuXi Biologics (WuXi Bio) have entered into an agreement that WuXi Biologics Germany GmbH will take over operations of one of Bayer’s final drug product manufacturing plants in Leverkusen, Germany, and purchase the associated equipment, in combination with a long-term lease contract for the building. Based on the manufacturing agreements to be negotiated, the WuXi Bio-operated plant shall serve as a back-up site for final product manufacturing of Kovaltry™ (antihemophilic factor (recombinant)), while Bayer’s drug substance and drug product facility in Berkeley, California, USA, will remain the major site for the manufacturing and filling of it. The transaction is expected to be concluded in the coming months subject to the satisfaction of customary closing conditions. Financial details were not disclosed.
About WuXi Biologics
WuXi Biologics (stock code: 2269.HK), a Hong Kong-listed company, is a leading global open-access biologics technology platform offering end-to-end solutions to empower organizations to discover, develop and manufacture biologics from concept to commercial manufacturing. WuXi Bio‘s track record and achievements demonstrate its commitment to global clients by providing a ONE-stop service offering with strong value proposition. With biopharmaceutical production planned in China, Ireland, Germany, Singapore, and the U.S., WuXi Bio will provide their biomanufacturing partners with a robust and premier-quality global supply chain network. For more information, please visit www.wuxibiologics.com.
This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer’s public reports which are available on the Bayer website at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.